CLEVELAND, April 18, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the company has partnered with
Minogue Medical Inc., a leading Canadian distributor of surgical
devices, operating room disposables, hospital equipment, and
simulators for medical education. As part of the exclusive
distribution agreement, Minogue Medical will market, sell, and
support ViewRay's MRIdian MRI-guided radiation therapy system
throughout Canada.
"The medical device market in Canada is strong and sophisticated, with a
high demand for innovative medical technologies," said Jim Alecxih, Chief Commercial Officer at
ViewRay. "We're pleased to partner with Minogue Medical to bring
MRIdian to the Canadian healthcare system and improve the accuracy
and precision of radiation therapy throughout the country."
Minogue Medical Inc., headquartered in Montreal, Quebec, is one the leading
distributors of medical equipment in Canada. For more than 30 years, Minogue
Medical has provided hospitals and medical clinics with
value-driven, best-to-market products, and ensured continued
assistance through a specialized field-based support team. The
company's core values revolve around best patient care and delivery
of state-of-the-art medical products.
"We are excited to continue to bring innovative technologies to
Canadian hospitals and patients," said Danny Minogue, CEO of Minogue Medical Inc.
"MRIdian's MRI-guided radiation therapy will help provide Canadians
with accurate, efficient, optimized care to help ensure excellent
outcomes for patients."
MRIdian provides continuous high-contrast imaging of soft tissue
during radiation therapy treatment to help clinicians position the
patient, track tumor and anatomical motion, and accurately target
treatment. MRIdian also enables on-table adaptive therapy, which
allows clinicians to adapt to changes and movement in the patient's
anatomy in real-time while the patient is being treated, bringing
even greater precision to radiation delivery.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
Forward-Looking Statements: This press release contains
forward-looking statements. Statements in this press release that
are not purely historical are forward-looking statements. These
statements are subject to risks and uncertainties that could cause
future results to differ materially from those referenced. Forward
looking statements include, but are not limited to references to
future MRIdian installations, clinical value and outcomes. Given
these uncertainties, the reader is advised not to place any undue
reliance on any forward-looking statements. Additional risk factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates, government and regulatory
uncertainty, including but not limited to obtaining authorizations
to market and new tariffs and trade restrictions, and overall
market conditions. These forward-looking statements are made as of
the date of this press release, and ViewRay assumes no obligation
to update the forward-looking statements, or to update the reasons
why actual results differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-partners-with-leading-canadian-distributor-to-bring-mri-guided-radiation-therapy-to-canada-300834364.html
SOURCE ViewRay, Inc.